Pharma & Healthcare

Global Non-invasive Insulin Market Outlook, In‑Depth Analysis & Forecast to 2031

Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Non-invasive Insulin market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Novo Nordisk
Sanofi
Eli Lilly
MannKind Corporation
Biocon
Janssen Pharmaceuticals
Adocia
Oramed Pharmaceuticals
Dance Biopharm
Medtronic
Verily Life Sciences
Zafgen
Senseonics
Bigfoot Biomedical
Segment by Type
Pills
Sprays
Others
Segment by Application
Hospital Pharmacies
Online Pharmacies
Drug Stores
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Non-invasive Insulin study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Non-invasive Insulin: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Non-invasive Insulin Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Pills
1.2.3 Sprays
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Non-invasive Insulin Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Online Pharmacies
1.3.4 Drug Stores
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Non-invasive Insulin Revenue Estimates and Forecasts 2020-2031
2.2 Global Non-invasive Insulin Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Non-invasive Insulin Sales Estimates and Forecasts 2020-2031
2.4 Global Non-invasive Insulin Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Non-invasive Insulin Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Non-invasive Insulin Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Pills Market Size by Manufacturers
3.5.2 Sprays Market Size by Manufacturers
3.5.3 Others Market Size by Manufacturers
3.6 Global Non-invasive Insulin Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Non-invasive Insulin Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Non-invasive Insulin Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Non-invasive Insulin Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Non-invasive Insulin Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Non-invasive Insulin Sales and Revenue by Type (2020-2031)
6.4 North America Non-invasive Insulin Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Non-invasive Insulin Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Non-invasive Insulin Sales and Revenue by Type (2020-2031)
7.4 Europe Non-invasive Insulin Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Non-invasive Insulin Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Non-invasive Insulin Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Non-invasive Insulin Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Non-invasive Insulin Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Non-invasive Insulin Sales and Revenue by Type (2020-2031)
9.4 Central and South America Non-invasive Insulin Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Non-invasive Insulin Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Non-invasive Insulin Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Non-invasive Insulin Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Non-invasive Insulin Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Novo Nordisk
11.1.1 Novo Nordisk Corporation Information
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk Non-invasive Insulin Product Models, Descriptions and Specifications
11.1.4 Novo Nordisk Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Novo Nordisk Non-invasive Insulin Sales by Product in 2024
11.1.6 Novo Nordisk Non-invasive Insulin Sales by Application in 2024
11.1.7 Novo Nordisk Non-invasive Insulin Sales by Geographic Area in 2024
11.1.8 Novo Nordisk Non-invasive Insulin SWOT Analysis
11.1.9 Novo Nordisk Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Non-invasive Insulin Product Models, Descriptions and Specifications
11.2.4 Sanofi Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Non-invasive Insulin Sales by Product in 2024
11.2.6 Sanofi Non-invasive Insulin Sales by Application in 2024
11.2.7 Sanofi Non-invasive Insulin Sales by Geographic Area in 2024
11.2.8 Sanofi Non-invasive Insulin SWOT Analysis
11.2.9 Sanofi Recent Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Corporation Information
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Non-invasive Insulin Product Models, Descriptions and Specifications
11.3.4 Eli Lilly Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Eli Lilly Non-invasive Insulin Sales by Product in 2024
11.3.6 Eli Lilly Non-invasive Insulin Sales by Application in 2024
11.3.7 Eli Lilly Non-invasive Insulin Sales by Geographic Area in 2024
11.3.8 Eli Lilly Non-invasive Insulin SWOT Analysis
11.3.9 Eli Lilly Recent Developments
11.4 MannKind Corporation
11.4.1 MannKind Corporation Corporation Information
11.4.2 MannKind Corporation Business Overview
11.4.3 MannKind Corporation Non-invasive Insulin Product Models, Descriptions and Specifications
11.4.4 MannKind Corporation Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 MannKind Corporation Non-invasive Insulin Sales by Product in 2024
11.4.6 MannKind Corporation Non-invasive Insulin Sales by Application in 2024
11.4.7 MannKind Corporation Non-invasive Insulin Sales by Geographic Area in 2024
11.4.8 MannKind Corporation Non-invasive Insulin SWOT Analysis
11.4.9 MannKind Corporation Recent Developments
11.5 Biocon
11.5.1 Biocon Corporation Information
11.5.2 Biocon Business Overview
11.5.3 Biocon Non-invasive Insulin Product Models, Descriptions and Specifications
11.5.4 Biocon Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Biocon Non-invasive Insulin Sales by Product in 2024
11.5.6 Biocon Non-invasive Insulin Sales by Application in 2024
11.5.7 Biocon Non-invasive Insulin Sales by Geographic Area in 2024
11.5.8 Biocon Non-invasive Insulin SWOT Analysis
11.5.9 Biocon Recent Developments
11.6 Janssen Pharmaceuticals
11.6.1 Janssen Pharmaceuticals Corporation Information
11.6.2 Janssen Pharmaceuticals Business Overview
11.6.3 Janssen Pharmaceuticals Non-invasive Insulin Product Models, Descriptions and Specifications
11.6.4 Janssen Pharmaceuticals Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Janssen Pharmaceuticals Recent Developments
11.7 Adocia
11.7.1 Adocia Corporation Information
11.7.2 Adocia Business Overview
11.7.3 Adocia Non-invasive Insulin Product Models, Descriptions and Specifications
11.7.4 Adocia Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Adocia Recent Developments
11.8 Oramed Pharmaceuticals
11.8.1 Oramed Pharmaceuticals Corporation Information
11.8.2 Oramed Pharmaceuticals Business Overview
11.8.3 Oramed Pharmaceuticals Non-invasive Insulin Product Models, Descriptions and Specifications
11.8.4 Oramed Pharmaceuticals Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Oramed Pharmaceuticals Recent Developments
11.9 Dance Biopharm
11.9.1 Dance Biopharm Corporation Information
11.9.2 Dance Biopharm Business Overview
11.9.3 Dance Biopharm Non-invasive Insulin Product Models, Descriptions and Specifications
11.9.4 Dance Biopharm Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Dance Biopharm Recent Developments
11.10 Medtronic
11.10.1 Medtronic Corporation Information
11.10.2 Medtronic Business Overview
11.10.3 Medtronic Non-invasive Insulin Product Models, Descriptions and Specifications
11.10.4 Medtronic Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Medtronic Recent Developments
11.11 Verily Life Sciences
11.11.1 Verily Life Sciences Corporation Information
11.11.2 Verily Life Sciences Business Overview
11.11.3 Verily Life Sciences Non-invasive Insulin Product Models, Descriptions and Specifications
11.11.4 Verily Life Sciences Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Verily Life Sciences Recent Developments
11.12 Zafgen
11.12.1 Zafgen Corporation Information
11.12.2 Zafgen Business Overview
11.12.3 Zafgen Non-invasive Insulin Product Models, Descriptions and Specifications
11.12.4 Zafgen Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Zafgen Recent Developments
11.13 Senseonics
11.13.1 Senseonics Corporation Information
11.13.2 Senseonics Business Overview
11.13.3 Senseonics Non-invasive Insulin Product Models, Descriptions and Specifications
11.13.4 Senseonics Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Senseonics Recent Developments
11.14 Bigfoot Biomedical
11.14.1 Bigfoot Biomedical Corporation Information
11.14.2 Bigfoot Biomedical Business Overview
11.14.3 Bigfoot Biomedical Non-invasive Insulin Product Models, Descriptions and Specifications
11.14.4 Bigfoot Biomedical Non-invasive Insulin Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Bigfoot Biomedical Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Non-invasive Insulin Industry Chain
12.2 Non-invasive Insulin Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Non-invasive Insulin Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Non-invasive Insulin Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Non-invasive Insulin Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Non-invasive Insulin Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Non-invasive Insulin Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Non-invasive Insulin Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Non-invasive Insulin Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Non-invasive Insulin Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Non-invasive Insulin Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Non-invasive Insulin Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Non-invasive Insulin Sales by Region (2020-2025) & (K Units)
Table 8. Global Non-invasive Insulin Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Non-invasive Insulin Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Non-invasive Insulin Sales Share by Manufacturers (2020-2025)
Table 12. Global Non-invasive Insulin Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Non-invasive Insulin Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Non-invasive Insulin by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-invasive Insulin as of 2024)
Table 16. Global Non-invasive Insulin Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Non-invasive Insulin Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Non-invasive Insulin Manufacturing Base and Headquarters
Table 19. Global Non-invasive Insulin Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Non-invasive Insulin Sales by Type (2020-2025) & (K Units)
Table 23. Global Non-invasive Insulin Sales by Type (2026-2031) & (K Units)
Table 24. Global Non-invasive Insulin Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Non-invasive Insulin Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Non-invasive Insulin ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Non-invasive Insulin Sales by Application (2020-2025) & (K Units)
Table 29. Global Non-invasive Insulin Sales by Application (2026-2031) & (K Units)
Table 30. Non-invasive Insulin High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Non-invasive Insulin Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Non-invasive Insulin Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Non-invasive Insulin ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Non-invasive Insulin Growth Accelerators and Market Barriers
Table 37. North America Non-invasive Insulin Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Non-invasive Insulin Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Non-invasive Insulin Growth Accelerators and Market Barriers
Table 40. Europe Non-invasive Insulin Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Non-invasive Insulin Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Non-invasive Insulin Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Non-invasive Insulin Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Non-invasive Insulin Growth Accelerators and Market Barriers
Table 45. Southeast Asia Non-invasive Insulin Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Non-invasive Insulin Investment Opportunities and Key Challenges
Table 47. Central and South America Non-invasive Insulin Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Non-invasive Insulin Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Non-invasive Insulin Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Novo Nordisk Corporation Information
Table 51. Novo Nordisk Description and Major Businesses
Table 52. Novo Nordisk Product Models, Descriptions and Specifications
Table 53. Novo Nordisk Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Novo Nordisk Sales Value Proportion by Product in 2024
Table 55. Novo Nordisk Sales Value Proportion by Application in 2024
Table 56. Novo Nordisk Sales Value Proportion by Geographic Area in 2024
Table 57. Novo Nordisk Non-invasive Insulin SWOT Analysis
Table 58. Novo Nordisk Recent Developments
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Major Businesses
Table 61. Sanofi Product Models, Descriptions and Specifications
Table 62. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Sanofi Sales Value Proportion by Product in 2024
Table 64. Sanofi Sales Value Proportion by Application in 2024
Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 66. Sanofi Non-invasive Insulin SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. Eli Lilly Corporation Information
Table 69. Eli Lilly Description and Major Businesses
Table 70. Eli Lilly Product Models, Descriptions and Specifications
Table 71. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Eli Lilly Sales Value Proportion by Product in 2024
Table 73. Eli Lilly Sales Value Proportion by Application in 2024
Table 74. Eli Lilly Sales Value Proportion by Geographic Area in 2024
Table 75. Eli Lilly Non-invasive Insulin SWOT Analysis
Table 76. Eli Lilly Recent Developments
Table 77. MannKind Corporation Corporation Information
Table 78. MannKind Corporation Description and Major Businesses
Table 79. MannKind Corporation Product Models, Descriptions and Specifications
Table 80. MannKind Corporation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. MannKind Corporation Sales Value Proportion by Product in 2024
Table 82. MannKind Corporation Sales Value Proportion by Application in 2024
Table 83. MannKind Corporation Sales Value Proportion by Geographic Area in 2024
Table 84. MannKind Corporation Non-invasive Insulin SWOT Analysis
Table 85. MannKind Corporation Recent Developments
Table 86. Biocon Corporation Information
Table 87. Biocon Description and Major Businesses
Table 88. Biocon Product Models, Descriptions and Specifications
Table 89. Biocon Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Biocon Sales Value Proportion by Product in 2024
Table 91. Biocon Sales Value Proportion by Application in 2024
Table 92. Biocon Sales Value Proportion by Geographic Area in 2024
Table 93. Biocon Non-invasive Insulin SWOT Analysis
Table 94. Biocon Recent Developments
Table 95. Janssen Pharmaceuticals Corporation Information
Table 96. Janssen Pharmaceuticals Description and Major Businesses
Table 97. Janssen Pharmaceuticals Product Models, Descriptions and Specifications
Table 98. Janssen Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Janssen Pharmaceuticals Recent Developments
Table 100. Adocia Corporation Information
Table 101. Adocia Description and Major Businesses
Table 102. Adocia Product Models, Descriptions and Specifications
Table 103. Adocia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Adocia Recent Developments
Table 105. Oramed Pharmaceuticals Corporation Information
Table 106. Oramed Pharmaceuticals Description and Major Businesses
Table 107. Oramed Pharmaceuticals Product Models, Descriptions and Specifications
Table 108. Oramed Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Oramed Pharmaceuticals Recent Developments
Table 110. Dance Biopharm Corporation Information
Table 111. Dance Biopharm Description and Major Businesses
Table 112. Dance Biopharm Product Models, Descriptions and Specifications
Table 113. Dance Biopharm Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Dance Biopharm Recent Developments
Table 115. Medtronic Corporation Information
Table 116. Medtronic Description and Major Businesses
Table 117. Medtronic Product Models, Descriptions and Specifications
Table 118. Medtronic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Medtronic Recent Developments
Table 120. Verily Life Sciences Corporation Information
Table 121. Verily Life Sciences Description and Major Businesses
Table 122. Verily Life Sciences Product Models, Descriptions and Specifications
Table 123. Verily Life Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Verily Life Sciences Recent Developments
Table 125. Zafgen Corporation Information
Table 126. Zafgen Description and Major Businesses
Table 127. Zafgen Product Models, Descriptions and Specifications
Table 128. Zafgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Zafgen Recent Developments
Table 130. Senseonics Corporation Information
Table 131. Senseonics Description and Major Businesses
Table 132. Senseonics Product Models, Descriptions and Specifications
Table 133. Senseonics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Senseonics Recent Developments
Table 135. Bigfoot Biomedical Corporation Information
Table 136. Bigfoot Biomedical Description and Major Businesses
Table 137. Bigfoot Biomedical Product Models, Descriptions and Specifications
Table 138. Bigfoot Biomedical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Bigfoot Biomedical Recent Developments
Table 140. Key Raw Materials Distribution
Table 141. Raw Materials Key Suppliers
Table 142. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 143. Milestones in Production Technology Evolution
Table 144. Distributors List
Table 145. Market Trends and Market Evolution
Table 146. Market Drivers and Opportunities
Table 147. Market Challenges, Risks, and Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources


List of Figures
Figure 1. Non-invasive Insulin Product Picture
Figure 2. Global Non-invasive Insulin Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Pills Product Picture
Figure 4. Sprays Product Picture
Figure 5. Others Product Picture
Figure 6. Global Non-invasive Insulin Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital Pharmacies
Figure 8. Online Pharmacies
Figure 9. Drug Stores
Figure 10. Non-invasive Insulin Report Years Considered
Figure 11. Global Non-invasive Insulin Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 13. Global Non-invasive Insulin Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Non-invasive Insulin Revenue Market Share by Region (2020-2031)
Figure 15. Global Non-invasive Insulin Sales (2020-2031) & (K Units)
Figure 16. Global Non-invasive Insulin Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Non-invasive Insulin Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Non-invasive Insulin Sales Volume Market Share in 2024
Figure 19. Global Non-invasive Insulin Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Pills Revenue Market Share by Manufacturer in 2024
Figure 22. Sprays Revenue Market Share by Manufacturer in 2024
Figure 23. Others Revenue Market Share by Manufacturer in 2024
Figure 24. Global Non-invasive Insulin Sales Market Share by Type (2020-2031)
Figure 25. Global Non-invasive Insulin Revenue Market Share by Type (2020-2031)
Figure 26. Global Non-invasive Insulin Sales Market Share by Application (2020-2031)
Figure 27. Global Non-invasive Insulin Revenue Market Share by Application (2020-2031)
Figure 28. North America Non-invasive Insulin Sales YoY (2020-2031) & (K Units)
Figure 29. North America Non-invasive Insulin Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Non-invasive Insulin Sales Revenue (US$ Million) in 2024
Figure 31. North America Non-invasive Insulin Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America Non-invasive Insulin Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Non-invasive Insulin Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America Non-invasive Insulin Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Non-invasive Insulin Sales YoY (2020-2031) & (K Units)
Figure 39. Europe Non-invasive Insulin Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Non-invasive Insulin Sales Revenue (US$ Million) in 2024
Figure 41. Europe Non-invasive Insulin Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe Non-invasive Insulin Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Non-invasive Insulin Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe Non-invasive Insulin Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 46. France Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Non-invasive Insulin Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific Non-invasive Insulin Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Non-invasive Insulin Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Non-invasive Insulin Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific Non-invasive Insulin Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Non-invasive Insulin Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific Non-invasive Insulin Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 61. India Non-invasive Insulin Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Non-invasive Insulin Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America Non-invasive Insulin Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Non-invasive Insulin Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Non-invasive Insulin Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America Non-invasive Insulin Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Non-invasive Insulin Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America Non-invasive Insulin Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Non-invasive Insulin Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Non-invasive Insulin Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Non-invasive Insulin Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa Non-invasive Insulin Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Non-invasive Insulin Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Non-invasive Insulin Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America Non-invasive Insulin Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Non-invasive Insulin Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa Non-invasive Insulin Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Non-invasive Insulin Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Non-invasive Insulin Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Non-invasive Insulin Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Non-invasive Insulin Revenue (2020-2025) & (US$ Million)
Figure 82. Non-invasive Insulin Industry Chain Mapping
Figure 83. Regional Non-invasive Insulin Manufacturing Base Distribution (%)
Figure 84. Global Non-invasive Insulin Production Market Share by Region (2020-2031)
Figure 85. Non-invasive Insulin Production Process
Figure 86. Regional Non-invasive Insulin Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies